- Kyowa Kirin’s Q2 net income was 10.15 billion yen, a decline of 56% year-over-year (y/y), missing the estimate of 14.48 billion yen.
- Net sales for the same period were 125.93 billion yen, which is a decline of 1.2% y/y, though it surpassed the estimate of 119.39 billion yen.
- For the first half of the year, core operating profit was recorded at 35.01 billion yen, a decrease of 21% y/y.
- The company maintains its year forecast with expectations of net income at 57.00 billion yen, slightly above the estimate of 56.14 billion yen.
- Kyowa Kirin anticipates net sales for the year to be 478.00 billion yen, exceeding the estimate of 475.12 billion yen.
- The projected dividend remains at 60.00 yen, aligning with the estimates.
- Market sentiments include 7 buy ratings, 6 hold ratings, and 1 sell rating.
Kyowa Kirin Co Ltd on Smartkarma
Analysts on Smartkarma, including Tina Banerjee, have recently covered Kyowa Kirin Co Ltd, providing valuable insights into the company’s performance and outlook.
In a report titled “Kyowa Kirin (4151 JP): Muted 1Q25 Result; 2025 Guidance Reaffirmed; Near-Term Pain to Continue,” it was highlighted that Kyowa Kirin reported flat revenue and a significant drop in profits for the first quarter of 2025. This was attributed to factors such as drug price revisions and market competition in Japan. The company also revised its 2025 revenue and profit forecasts downwards, indicating a challenging near-term outlook. Tina Banerjee expressed a bearish sentiment on Kyowa Kirin, emphasizing that the company’s shares have declined by approximately 15% since the previous analysis. The overall assessment suggests that Kyowa Kirin may face continued difficulties before seeing a potential recovery in the future.
A look at Kyowa Kirin Co Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Having assessed Kyowa Kirin Co Ltd based on the Smartkarma Smart Scores, the company demonstrates a balanced performance across key factors. With moderate scores in Value, Dividend, and Growth at 3, Kyowa Kirin Co Ltd showcases stable fundamentals for investors. Moreover, the company’s above-average score in Resilience at 4 reflects its capacity to weather market fluctuations. Additionally, Kyowa Kirin Co Ltd excels in Momentum with a high score of 5, indicating strong market presence and potential for upward growth.
In summary, Kyowa Hakko Kirin Co., Ltd. is a pharmaceutical company that develops, manufactures, and markets a range of products utilizing advanced genetic technology. With a solid overall outlook based on the Smartkarma Smart Scores, investors may find Kyowa Kirin Co Ltd to be a promising long-term investment option, supported by its resilient performance and positive market momentum.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
